Zobrazeno 1 - 10
of 130
pro vyhledávání: ''
Autor:
Akiko Miyagi Maeshima, Emi Noguchi, Kan Yonemori, Maki Tanioka, Kazuki Sudo, Tadaaki Nishikawa, Yuki Kojima, Masaki Uchihara, Tatsunori Shimoi
Publikováno v:
International Journal of Clinical Oncology. 26:2275-2281
Adrenocortical carcinoma (ACC) is a rare and aggressive disease that is often diagnosed at an advanced stage. There is no standard treatment for metastatic ACC; EDP-M (etoposide, doxorubicin, and cisplatin plus mitotane) is one treatment option. A ra
Autor:
Yoichi Nakanishi, Yasutaka Chiba, Masahiro Fukuoka, Makoto Oda, Kohei Yokoi, Hiroshi Semba, Hiroaki Nomori, Takashi Seto, Shunichi Negoro, Nobuyuki Katakami, Mitsunori Ohta, Mototsugu Shimokawa, Masafumi Yamaguchi, Toshiyuki Sawa, Masahiko Higashiyama, Kazuhiko Nakagawa, Motohiro Yamashita, Tetsuya Mitsudomi, Norihiko Iked, Hirohito Tada, Hideo Saka
Publikováno v:
International Journal of Clinical Oncology. 26:2216-2223
Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has minor adverse events (AEs).
Autor:
Yukinori Kurokawa, Junya Fujita, Tomono Kawase, Yutaka Kimura, Hiroshi Imamura, Hisato Kawakami, Masahiro Goto, Kazuhiro Nishikawa, Norimasa Fukushima, Shugo Ueda, Naotoshi Sugimoto, Jin Matsuyama, Taroh Satoh, Daisuke Sakai, Takao Tamura, Toshio Shimokawa
Publikováno v:
International Journal of Clinical Oncology. 26:1871-1880
To compare irinotecan-alone, paclitaxel-alone, and each combination chemotherapy with S-1 in patients with advanced gastric cancer (AGC) that is refractory to S-1 or S-1 plus cisplatin (SP). Patients with AGC after first-line chemotherapy with S-1 or
Autor:
Marialuisa Appetecchia, Tania D’Amico, Carla Scaroni, Corrado De Vito, Valeria Mercuri, Filippo Ceccato, Denise Costa, Rosa Lauretta, Patrizia Gargiulo
Publikováno v:
International Journal of Clinical Oncology
Background Acromegaly is a rare disease due to chronic growth hormone (GH) excess and the consequent increase in insulin-like growth factor-1 (IGF-1) levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. The
Autor:
Yosuke Kawashima, Tomoya Kuda, Kana Watanabe, Kazuhiro Usui, Kei Takamura, Shunichi Sugawara, Taku Nakagawa, Yuka Fujita, Akimasa Sekine, Akira Inoue, Kenya Kanazawa, Toshiyuki Harada, Naoto Morikawa
Publikováno v:
International Journal of Clinical Oncology. 26:515-522
A subset analysis of the CA031 trial showed significant improvement in the overall response rate after administration of carboplatin plus weekly albumin-bound paclitaxel compared to carboplatin plus paclitaxel for squamous cell carcinoma of the lung
Autor:
Masato Matsuyama, Takafumi Mie, Naoki Sasahira, Takashi Sasaki, Akiyoshi Kasuga, Koshiro Fukuda, Masato Ozaka, Tsuyoshi Takeda, Takaaki Furukawa, Yuto Yamada
Publikováno v:
International Journal of Clinical Oncology. 26:543-551
Drug-induced interstitial lung disease (ILD) is one of the most serious adverse events with a high mortality rate and represents a serious clinical problem. However, gemcitabine plus nab-paclitaxel (GnP)-induced ILD in pancreatic cancer (PC) patients
Autor:
Ryo Ariyasu, Noriko Yanagitani, Fumiyoshi Ohyanagi, Ken Uchibori, Tsukasa Hasegawa, Makoto Nishio, Keita Kudo, Shingo Nishikawa, Yuichi Tambo, Atsushi Horiike, Satoru Kitazono
Publikováno v:
International Journal of Clinical Oncology. 26:507-514
We assessed the efficacy and safety of bevacizumab and S-1 chemotherapy for patients with previously treated advanced non-squamous non-small-cell lung cancer (NSCLC). This was a prospective single-arm study, including patients with non-squamous NSCLC
Autor:
Takashi Kikuchi, Hiroaki Nagano, Michio Inukai, Tomohiro Nishina, Ichiro Moriyama, Takeshi Shiraishi, Hiroaki Tanioka, Ryosuke Yoshida, Kenji Tsuchihashi, Kimiyasu Nozaka, Michiya Kobayashi, Yasuro Kurisu, Toshiyoshi Fujiwara, Masashi Miguchi, Takeshi Nagasaka, K. Shinozaki, Toshihiko Matsumoto, Yasuhiro Yuasa, Takeshi Yamada, Junichiro Nasu
Publikováno v:
International Journal of Clinical Oncology
Purpose FOLFOXIRI plus bevacizumab is regarded as a first-line therapeutic option for selected patients with metastatic colorectal cancer (mCRC). Our aim was to assess the efficacy and safety of induction treatment with FOLFOXIRI plus bevacizumab in
Autor:
Takahisa Abe, Hirotoshi Dosaka-Akita, Takuro Noguchi, Yoshihito Ohhara, Tomohiro Goda, Jun Taguchi, Akihiro Homma, Satoshi Kano, Takatsugu Mizumachi, Yasushi Shimizu, Ichiro Kinoshita, Shin Ariga, Rio Honma, Toraji Amano, Miki Takahara, Satoshi Takeuchi
Publikováno v:
International Journal of Clinical Oncology. 26:51-58
The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in patients who cannot tolerate platinum-based regimens has not been clarified. We aimed to develop a new treatment
Publikováno v:
International Journal of Clinical Oncology. 26:163-168
Background: Tuberous sclerosis complex (TSC) is a rare disease, with an autosomal dominant mode of inheritance, that results in systemic hamartoma. Renal angiomyolipoma (AML) is observed in 50-80% of TSC patients. Everolimus is recommended as an init